(Q35171274)

6 August 2017

title

ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors (English)

1 reference

6 August 2017

main subject

multiple drug resistance

1 reference

Jiexin Deng

1

1 reference

6 August 2017

Jie Shao

series ordinal

2

1 reference

6 August 2017

John S Markowitz

series ordinal

3

1 reference

6 August 2017

Guohua An

series ordinal

4

1 reference

6 August 2017

publication date

20 May 2014

1 reference

6 August 2017

published in

Pharmaceutical Research

1 reference

6 August 2017

volume

31

1 reference

6 August 2017

issue

9

1 reference

6 August 2017

page(s)

2237-2255

1 reference

Doxorubicin: the good, the bad and the ugly effect

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Cisplatin: a review of toxicities and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Tyrosine kinase inhibitors: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Chronic myelogenous leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Resistance in the land of molecular cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Pharmacokinetic considerations for new targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Regulation and targets of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Human squamous cell lung cancers express increased epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Lapatinib: current status and future directions in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The vascular endothelial growth factor family and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Kinase inhibitors in cancer therapy: a look ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The prospects of pazopanib in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Smart drugs: tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

An inventory of the human ABC proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

ABC multidrug transporters: structure, function and role in chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Role of the breast cancer resistance protein (ABCG2) in drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The human ATP-binding cassette (ABC) transporter superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Multiple drug resistance mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec® ) across the mouse blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Brain distribution of cediranib is limited by active efflux at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Experience with sorafenib and adverse event management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

P-glycoprotein, multidrug resistance and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Structural, mechanistic and clinical aspects of MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

ABCG2 transports sulfated conjugates of steroids and xenobiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

The pathway to signal achievement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1389-0

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

21 January 2018

1 reference

12 December 2020

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer

1 reference

12 December 2020

Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells

1 reference

12 December 2020

Glutathione, ascorbate, and cellular protection.

1 reference

12 December 2020

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

1 reference

12 December 2020

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas

1 reference

12 December 2020

Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future

1 reference

12 December 2020

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

1 reference

12 December 2020

Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis

1 reference

12 December 2020

Expression of a multidrug resistance gene in human cancers

1 reference

12 December 2020

Targeting tyrosine kinases in cancer: the second wave

1 reference

12 December 2020

Anthracyclines in the treatment of cancer. An overview

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

1 reference

12 December 2020

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer

1 reference

12 December 2020

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux

1 reference

12 December 2020

Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines

1 reference

12 December 2020

Gefitinib reverses breast cancer resistance protein-mediated drug resistance

1 reference

12 December 2020

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

12 December 2020

Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins.

1 reference

12 December 2020

Molecular mechanisms of Bcr-Abl-induced oncogenesis

1 reference

12 December 2020

Therapeutic application of anti-growth factor receptor antibodies

1 reference

12 December 2020

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels

1 reference

12 December 2020

RTK mutations and human syndromes: when good receptors turn bad

1 reference

12 December 2020

Receptor protein-tyrosine kinases and their signal transduction pathways

1 reference

12 December 2020

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

12 December 2020

The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)

1 reference

12 December 2020

10.1007/S11095-014-1389-0

Identifiers

DOI

1 reference

6 August 2017

1 reference